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A key challenge facing global mental health has been addressing the large ‘treatment gaps’ for 
neuropsychiatric disorders, to which large ‘detection gaps’ contribute significantly. The majority 
of these conditions are diagnosed either very late, or not at all.1 Low- and middle-income countries 
(LMICs) in particular present three barriers: low help-seeking behavior, in part due to limited 
awareness and stigma associated with mental disorders; paucity of mental health professionals to 
conduct diagnostic assessments; and reliance on diagnostic interviews many of which are time-
intensive or proprietary and may not be cross-culturally valid.2 Identifying biomarkers that could 
aid early detection of mental disorders is a major goal for neuroscience research. Biomarkers may 
be defined as “any characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”.3 Identification and characterization of biomarkers offers a tantalizing new 
translational opportunity to address detection gaps in LMICs by enabling point-of-care detection 
by non-specialist health workers. We illustrate our proposal through the example of Autism 
Spectrum Disorders (ASD). 
The priority placed on early detection of ASD has been recognized by high-income countries' 
(HICs) development of large consortia that integrate multidisciplinary expertise for biomarker 
discovery, such as the EU-AIMS (www.eu-aims.eu) and the ABC-CT (www.asdbiomarkers.org). 
A variety of biomarkers, including genetic variations, proteomic and metabolic profiles, brain 
anatomy and function, and markers of cognitive and behavioral deficits offer promise in 
discriminating typically developing children from those with ASD.4 For LMICs to benefit from 
such research, however, biomarker screening and detection methods must be low-cost, scalable, 
acceptable to the end user and feasible for use in community settings and for delivery by non-
specialist frontline workers. Additionally, selected biomarkers must be highly sensitive and 
specific, being able to identify children with ASD during community-level screening, while 
limiting the number of false positives to avoid straining the limited health resources in LMICs and 
minimizing adverse social consequences to those who do not have this condition. Such ‘point-of-
care’ detection tools would pave the way for targeted referral to specialists for confirmatory 
diagnostic assessments and early intervention programs. 
Among direct child assessment measures, atypical eye gaze is one of the most promising 
biomarkers of ASD.5 Various measures of neural connectivity and specific neural functions are 
also associated with ASD.6 Bearing scalability in mind, portable eye-tracking technology and 
electroencephalography currently have the most promise for ASD screening. These technologies 
are non-invasive, applicable from infancy to adulthood and can be acquired on commercially 
available, portable platforms. While near infrared spectroscopy shares some of these advantages, 
there is currently limited evidence available to inform on its potential for use in detection of ASD. 
LMICs can assess the potential of these promising biomarkers when evaluated on rapidly evolving 
portable hardware, in less controlled recording environments, administered by non-specialist 
community workers. 
Although complex interactions between genetic vulnerability and environmental factors have long 
been viewed as being causal to ASD, apart from a few single-gene disorders, no common set of 
loci can reliably predict ASD.4 The identification of biomarkers in peripheral blood, such as altered 
serotonin and glutamate and GABA levels,7 could be particularly useful because the logistics of 
cold-chain transport of biomaterials to analytical laboratories have been established in most 
countries. Currently, the requirement of state-of-the-art, expensive, laboratory-based genomic and 
proteomic technologies to assess these biomarkers poses a limitation in LMICs; however, as with 
3 
 
polymerase chain reaction technologies for the diagnosis of infectious diseases, there is a potential 
for investment in their adaptation for scalability if diagnostic properties prove to be robust.  
Mobile health (mHealth) platforms have immense potential to address the multiple challenges 
illustrated above.8 In the context of ASD, while there are a number of tablet-based interventions 
readily available,9 there are relatively few tablet-based detection tools. For instance, screening 
questionnaires such as the Modified Checklist for Autism in Toddlers and the Social 
Communication Disorder Checklist, which are now being used routinely in some HICs, can readily 
be adapted onto mobile platforms from traditional paper-pencil methods, containing programmed 
algorithms for scoring. A first step to such mHealth adaptations is to ensure availability of 
culturally validated tools for screening and diagnosis in local languages. These could be 
supplemented by videos demonstrating typical and ASD behavioural biomarkers to assist parents 
in diverse cultural contexts to respond accurately to questions (http://asdetect.org/). Mobile 
applications containing automatic coding and analysis of video recordings of a child’s facial 
expressions are also being currently tested.10 Eye-tracking assessments could also be fully 
integrated within such mHealth platforms. 
While ASD cannot yet be definitively differentiated from typical development in an individual on 
the basis of any single biomarker, mHealth platforms offer the potential of combining and 
triangulating information from assessment of multiple biomarkers. Bayesian statistical models can 
be used to estimate the probability of ‘caseness’ based on findings drawn from a combination of 
assessment methods to improve the accuracy of ASD risk prediction (Figure 1). In addition, the 
integration of big data analytics and machine learning algorithms during development of such a 
screening platform will allow refinement of screening algorithms through feedback of data on the 
actual diagnosis of the individual. Such data from large-scale population-based surveillance using 
an integrated mHealth platform may ultimately provide the evidence base for development of a 
point-of-care diagnostic tool for ASD. 
Despite a growing body of evidence on ASD biomarkers, and similar research in other mental 
disorders, data on their application at the community level or in LMICs are limited. In parallel, 
technologies need to evolve to fulfil the criteria of scalability and demonstrate potential for use in 
natural, uncontrolled settings. Such advances also would benefit low-resource settings within 
HICs. Further, the expansion of research initiatives to LMIC populations would allow evaluation 
of biomarkers at global scales, incorporating diverse genetic and socio-cultural milieu. This is an 
opportune time for neuroscientists, clinicians, public health researchers and engineers to establish 
collaborative networks to design innovative solutions for detection of mental disorders and to usher 
in a new era for global mental health.11  
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Figure Legend 
Figure 1: Development of point-of-care ASD detection/diagnostic tool 
a) Promising biomarkers, assessed using scalable technologies, can be integrated onto a 
mobile screening platform. Probabilistic modelling can identify thresholds for each 
biomarker individually and in combination to detect ASD. 
b) Using scalable technologies, validation of the ‘biomarker package’ in large-scale 
population studies will allow machine learning algorithms to refine biomarker thresholds 
for a point-of-care diagnostic/detection tool for ASD. 
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